Press Releases

Tel Aviv, Israel— December 7, 2017 – InspireMD, Inc.  (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that Professor Ralf Kolvenbach, head of the Vascular Surgery and Endovascular Therapy Department, and Medical Director of the Catholic Hospital, Düsseldorf, Germany, presented the preliminary results of a 50… Read More

No procedure or device related adverse events at 24 months Results presented at the 2017 VEITHsymposium in New York and ICI Meeting 2017 in Tel Aviv Tel Aviv, Israel— December 5, 2017 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced the preliminary… Read More

Tel Aviv, Israel— December 4, 2017 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed Diverse Devices Pty Ltd as its exclusive distributor for Australia and New Zealand, and has signed Do Gia Production and Trading JSC as its exclusive distributor in… Read More

Tel Aviv, Israel— November 29, 2017 – InspireMD, Inc. (NYSE MKT:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it entered into a securities purchase agreement with an institutional investor for the issuance and sale of 750 shares of InspireMD’s Series D Preferred Stock for aggregate gross proceeds… Read More

Tel Aviv, Israel—November 7, 2017 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in Embolic Prevention Systems (EPS) / thrombus management technologies and neurovascular devices, today announced preliminary results for the third quarter ending September 30, 2017. James Barry, PhD, Chief Executive Officer of InspireMD, commented, “Not only did we achieve a 90% year-over-year increase in sales of… Read More

Tel Aviv—November 1, 2017 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that it will host a conference call on Wednesday, November 8th at 8:00 a.m. Eastern Time to discuss the company’s financial results for the third quarter ended September 30, 2017, as well… Read More

Prof. Waclaw Kuczmik performed successful case treating a patient with carotid artery disease with CGuard™ EPS in Katowice Clinical Hospital Tel Aviv, Israel – October 25, 2017 – InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that Prof. Waclaw Kuczmik, Head of the… Read More

Prof. Waclaw Kuczmik performed successful case treating a patient with carotid artery disease with CGuard™ EPS in Katowice Clinical Hospital Tel Aviv, Israel – October 25, 2017 – InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that Prof. Waclaw Kuczmik, Head of the… Read More

Tel Aviv, Israel – October 24, 2017 – InspireMD, Inc. (NYSE AMER:NSPR) (NYSE AMER:NSPR.WS) (“InspireMD” or the “Company”), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that the New York Stock Exchange has accepted the Company’s plan to regain compliance with the NYSE American’s stockholder’s equity continued listing standard… Read More

Tel Aviv, Israel—October 12, 2017 – InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced it has signed an agreement with CorpMedical Chile Ltda, a leading medical distributor in Chile, with its headquarters in Santiago de Chile, to distribute the MGuard Prime™ Embolic Protection System (EPS)… Read More